These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20469618)

  • 61. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
    Kavuru M; Melamed J; Gross G; Laforce C; House K; Prillaman B; Baitinger L; Woodring A; Shah T
    J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1108-16. PubMed ID: 10856143
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Accuracy of death certificates in COPD: analysis from the TORCH trial.
    Drummond MB; Wise RA; John M; Zvarich MT; McGarvey LP
    COPD; 2010 Jun; 7(3):179-85. PubMed ID: 20486816
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C; Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Willits LR; Yates JC; Vestbo J
    Eur Respir J; 2009 Sep; 34(3):641-7. PubMed ID: 19443528
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fluticasone propionate/salmeterol combination.
    Lipworth BJ
    J Allergy Clin Immunol; 2001 Apr; 107(4):746. PubMed ID: 11295673
    [No Abstract]   [Full Text] [Related]  

  • 67. COPD guidelines: the important thing is not to stop questioning.
    Fabbri LM; Boschetto P; Mapp CE; ;
    Am J Respir Crit Care Med; 2007 Sep; 176(6):527-8. PubMed ID: 17823358
    [No Abstract]   [Full Text] [Related]  

  • 68. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.
    Celli B; Vestbo J; Jenkins CR; Jones PW; Ferguson GT; Calverley PM; Yates JC; Anderson JA; Willits LR; Wise RA;
    Am J Respir Crit Care Med; 2011 Feb; 183(3):317-22. PubMed ID: 20813884
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD.
    Hanania NA; Kalberg C; Yates J; Emmett A; Horstman D; Knobil K
    Pulm Pharmacol Ther; 2005; 18(1):19-22. PubMed ID: 15607123
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.
    Currie GP; Stenback S; Lipworth BJ
    Br J Clin Pharmacol; 2003 Jul; 56(1):11-7. PubMed ID: 12848770
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Increased dosage of inhaled corticosteroids or addition of salmeterol in symptomatic asthma].
    Jébrak G
    Presse Med; 2000 Sep; 29(27):1512-3. PubMed ID: 11045121
    [No Abstract]   [Full Text] [Related]  

  • 75. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
    Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening AP; Haahtela T; Holgate ST; Picado C; Menten J; Dass SB; Leff JA; Polos PG
    BMJ; 2003 Oct; 327(7420):891. PubMed ID: 14563743
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
    Miller DP; Watkins SE; Sampson T; Davis KJ
    Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
    Dal Negro RW; Pomari C; Tognella S; Micheletto C
    Pulm Pharmacol Ther; 2003; 16(4):241-6. PubMed ID: 12850128
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for chronic obstructive pulmonary disease: possible confounding effect of treatment withdrawal?
    Brown SM
    Ann Intern Med; 2007 Dec; 147(12):882; author reply 882-3. PubMed ID: 18087061
    [No Abstract]   [Full Text] [Related]  

  • 80. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.
    Vestbo J; Soriano JB; Anderson JA; Calverley P; Pauwels R; Jones P;
    Respir Med; 2004 Nov; 98(11):1045-50. PubMed ID: 15526804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.